From: First experiences with 177Lu-PSMA-617 therapy for recurrent or metastatic salivary gland cancer
Pt 1 | Pt 2 | Pt 3 | Pt 4 | Pt 5 | Pt 6 | |
---|---|---|---|---|---|---|
Sex | F | M | M | F | M | F |
Age at diagnosis | 56 | 41 | 32 | 74 | 32 | 39 |
Year of diagnosis | 2005 | 2013 | 2006 | 2016 | 2004 | 2017 |
Tumour type | AdCC | AdCC | AdCC | Adenocarcinoma NOS | Acinic cell carcinoma | AdCC |
Tumour site | Hard palate | Parotid | Cheek mucosa | Parotid | Parotid | Submandibular gland |
Treatment | Local excision | Local excision + radiotherapy | Local excision + radiotherapy | Palliative radiotherapy | Local excision + radiotherapy | Local excision + radiotherapy |
Disease | ||||||
Locoregional recurrence | – | Parapharyngeal, intracranial | – | – | – | Parapharyngeal, lymphatic |
Distant metastases | Lung, Liver | - | Lung, Bone (vertebra) | Bone (skull, vertebra) | Lymphatic (inguinal), Lung, Bone (vertebra) | - |
Completed ‘conventional’ palliative treatment | None | None | Chemotherapy (CAP), radiotherapy | Radiotherapy | Chemotherapy (CAP), radiotherapy | Chemotherapy (CAP), radiotherapy |
PSMA expression on IHC (%) | 5 | 30 | N/A | 30 | 95 | 30 |
SUVmax VOI before treatment | 3.5 lung | 6.5 intracranial | 10.2 pelvis | 12.5 pelvis | 9.7 pelvis | 7.0 parapharyngeal |
Treatment | ||||||
Diagnosis to 177Lu-PSMA (years) | 12 | 6 | 12 | 1 | 14 | 2 |
No. cycles | 4 | 4 | 2 | 1 | 2 | 2 |
SUVmax VOI after treatment | N/A | 4.5 | N/A | N/A | 17.6 | 9.4 |
Reason of discontinuation | End of protocol | End of protocol | Disease progression, adverse effects | Demotivation due to side-effects | Disease progression | Disease progression |
Side effects | ||||||
Side effects (CTCAE grade) | Fatigue (2) Dyspnoea (2) Nausea (1) | Fatigue (1) Nausea (1) Vomiting (1) Xerostomia (1) | Fatigue (1) Bone pain (2) Thrombocytopenia (3) | Fatigue (1) Xerostomia (1) | Fatigue (1) Xerostomia (1) Bone pain (2) | Fatigue (1) Xerostomia (2) |
Response | ||||||
Clinical | Less dyspnoea, less fatigue | Improved facial expression and sensibility, less fatigue | Disease progression | N/A | Significant pain relief (6 weeks) | Diminution of facial nerve palsy, pain relief |
Radiological | Stable lung lesions, minimal progression of liver metastases | Stable disease, decrease SUVmax | Disease progression | N/A | Disease progression | Disease progression |
Follow-up (months after first treatment) | Deceased (7) | Alive with disease (36) | Deceased (3) | Deceased (5) | Deceased (6) | Deceased (9) |